Table: Otsuka -2023 group forecast
Table: Otsuka -Q1 group results
Table: Otsuka -2022 parent results
Table: Otsuka -2022 group results
Brief: Otsuka And Lundbeck Announce U.S. FDA Acceptance And Priority Review Of sNDA For Brexpiprazole For Treatment Of Agitation Associated With Alzheimer's Dementia
Table: Otsuka - 9-MTH group results
Table: Otsuka - 6-MTH group results
Lundbeck shares swell on positive results for dementia drug
Lundbeck, Otsuka announce positive phase III results for Alzheimer's agitation drug
Table: Otsuka -Q1 group results
Table: Otsuka -2021 group results
Table: Otsuka -2021 parent results
Table: Otsuka -2021 parent results
Table: Otsuka -2021 group results
Table: Otsuka - 9-MTH group results
Table: Otsuka - 6-MTH group results
Table: Otsuka -Q1 group results
Table: Otsuka -2020 group results
Table: Otsuka -2020 parent results